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Abstract
Introduction: Decompensated diabetes is a major risk factor in the development of periodontal diseases. This leads to disturbances of 
carbohydrates, protein, and fat and morphological changes in many organs. These changes also apply to the masticatory system, especially 
periodontal tissues. The aim of the study was to assess the periodontal status and periodontal treatment needs in patients with non-con-
trolled diabetes type 1 and type 2 (HbA1c > 7%), and to compare the results with the data obtained in a group of generally healthy patients. 
Material and methods: The study included 275 patients, 155 of them were patients with non-controlled diabetes during hospitalisation 
(study group), while 120 subjects constituted the control group of healthy people. The study excluded edentulous people. CPITN index 
(according to Ainamo et al.) was used to assess the periodontal state and periodontal treatment needs. 
Results: The average level of glycated haemoglobin HbA1C among patients in the study group was 9.43% in women and slightly more 
at 9.57% in men. The periodontal status in healthy people was satisfactory, dominated by the maximum values of CPITN = 0, CPITN = 
1, and CPITN = 2. The study group more frequently revealed the maximum values of CPITN = 3 and CPITN = 4. This shows the more 
advanced periodontal changes in this group. Due to the bad condition of the periodontium, the periodontal treatment needs proved to 
be far greater in the study group and related primarily to comprehensive specialist treatment (TN3). 
Conclusions: Decompensated diabetes may be an important cause of changes in periodontal tissues and may cause a significant loss of 
masticatory function in patients. (Endokrynol Pol 2015; 66 (5): 428–433)
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Streszczenie
Wstęp: Niewyrównana cukrzyca jest jednym z głównych czynników ryzyka w powstawaniu i rozwoju schorzeń tkanek przyzębia. Pro-
wadzi do zaburzeń gospodarki węglowodanowej, białkowej i tłuszczowej oraz zmian morfologicznych w wielu narządach. Zmiany te 
dotyczą również narządu żucia a przede wszystkim tkanek przyzębia. Celem pracy była ocena stanu przyzębia i periodontologicznych 
potrzeb leczniczych u pacjentów z niewyrównaną cukrzycą typu 1 i typu 2 ( HbA1c > 7% ) oraz porównanie wyników badań z danymi 
otrzymanymi w grupie osób ogólnie zdrowych.
Materiał i metody: Badaniem objęto 275 pacjentów, 155 z nich to chorzy z niewyrównaną cukrzycą w trakcie hospitalizacji (grupa bada-
na), zaś 120 osób stanowiło grupę porównawczą ludzi zdrowych. Z badania wykluczono osoby z bezzębiem. Do oceny stanu przyzębia 
i periodontologicznych potrzeb leczniczych zastosowano wskaźnik CPITN (według Ainamo i wsp.). 
Wyniki: Przeciętny poziom hemoglobiny glikowanej HbA1C wśród pacjentów z grupy badanej wynosił ogółem 9,43% u kobiet, 
a u mężczyzn nieznacznie więcej bo 9,57%. Stan przyzębia u osób ogólnie zdrowych był zadowalający, przeważały maksymalne wartości 
CPITN = 0, CPITN = 1 i CPITN = 2. W grupie badanej natomiast częściej występowały maksymalne wartości CPITN = 3 oraz CPITN = 4, 
co świadczy o bardziej zaawansowanych zmianach w przyzębiu w tej grupie. Wynikające ze złego stanu przyzębia potrzeby lecznicze 
okazały się zdecydowanie większe w grupie badanej i dotyczyły przede wszystkim kompleksowego leczenia specjalistycznego (TN3).
Wnioski: Niewyrównana cukrzyca może stanowić istotną przyczynę zmian w obrębie tkanek przyzębia i wpływać na znaczną utratę 
funkcji narządu żucia u osób chorych. (Endokrynol Pol 2015; 66 (5): 428–433)
Słowa kluczowe: jama ustna; przyzębie; niewyrównana cukrzyca 
Introduction
Among the systemic metabolic diseases affecting the 
periodontal tissues, diabetes is the most common, 
especially non-controlled [1].
Diabetes (diabetes mellitus) is considered to be 
a social disease. According to epidemiological data, 
from 3 to 6 per cent of the population suffers from it 
[2]. The World Health Organisation predicts that by 
2025 the number of people with diabetes will increase 
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Material and methods
The study included 275 patients, 155 of them were 
patients with non-controlled type 1 diabetes (subgroup I) 
and type 2 (subgroup II) during hospitalisation — the 
study group. The control group of healthy people 
consisted of 120 patients without diabetes or clinically 
overt comorbidities. Edentulous people were excluded. 
Patients declared their consent in writing. The study 
obtained the consent of the Bioethics Committee of the 
Medical University of Białystok (Nr R-I-002/47/2008). 
The study was conducted in a dental surgery, under 
artificial light, and using a dental set and standardised 
probe (periodondometer WHO). The obtained data was 
applied to specially designed examination cards. The 
CPITN index, proposed by Ainamo et al., was used to 
assess the periodontal status and periodontal treatment 
needs [13–15). The evaluation was done on a scale of 
five graded criteria as follows:
0 = healthy periodontium, the patient does not 
require treatment — TN0
1 = bleeding after gentle probing, oral hygiene 
instruction is indicated — TN1
2 = tartar (over or subgingival), the additional re-
moval of tartar/scaling is necessary — TN2
3 = depth of the gingival pockets from 3.5 to 5.5 mm, 
also needs from the point TN2
4 = deepened pockets depth > 5.5 mm, the 
additional need for a comprehensive periodontal pro-
cedures, including surgery — TN3.
The index was evaluated in the six following oral 
sections (sextets):
17–14, 13–23, 24–27
47–44, 43–33, 34–37
The results were statistically analysed. The study 
hypotheses were verified using the t-Student test for 
two means and “u” test for two frequencies. Differences 
for which p < 0.05 were statistically significant.
Results
The structure of both groups is presented in Table I, 
while the number and percentage of edentulous pa-
tients (excluded from the study) is shown in Table II. The 
average level of glycated HbA1C among patients in the 
study group was 9.43% in women and slightly higher 
in men at 9.57% (Table III). In subgroup I it reached 
an average level of 9.47%, and it was slightly higher 
in women (9.51%) than in men (9.43%). In subgroup 
II it was 9.53%; 9.36% in women and 9.68% in men, 
respectively.
The smallest proportion of patients in the study 
group, at only 3.6%, showed the maximum value of 
index CPITN = 0, i.e. healthy periodontium (Table IV). 
to 5.4%, and up to 25% in the population between 
65 and 74 years of age [3–5]. The long-term conse-
quences of the disease significantly affect overall 
morbidity and mortality, and shorten life expectancy 
by about 30% [2, 6].
Diabetes can be defined as a systemic disease char-
acterised by hyperglycaemia resulting from the defect 
of insulin secretion or action [6].
There are the following types of diabetes: type 
1 diabetes (autoimmunological or idiopathic aetiol-
ogy), type 2 diabetes and other specific types (e.g. 
in the course of infectious diseases, chronic pancrea-
titis, endocrinopathies, genetic diseases, associated 
with taking certain medications), and gestational 
diabetes [4, 6].
This disease is characterised by the risk of complica-
tions, both acute and chronic [7]. All chronic diabetic 
complications are likely to have a vascular background. 
They can be divided into non-specific macroangiopathy 
and specific microangiopathy. Analysing the vascular 
changes in diabetes, their impact on the periodontal 
tissues seems to be indisputable: the narrowing of 
capillaries and precapillaries hinders the transport of 
nutrients [1, 8]. The impairment of oxygen diffusion 
and the elimination of unnecessary metabolites lead to 
the physiological imbalance and increase the sensitivity 
to the periodontal damage [9]. According to Matthews 
[10], chronic complications of diabetes are associated 
with persistent hyperglycaemia, which results in the 
formation of advanced glycation end products (AGEs). 
They act by “arming” the endothelial cells and mono-
cytes, making them more sensitive to stimuli that induce 
inflammatory mediators. Because, as a result of non-
controlled diabetes, AGEs accumulate in plasma and 
tissues, it can be assumed that the periodontal tissues 
with the high levels of AGEs have greater vascular per-
meability, increased loss of collagen fibres, and exhibit 
accelerated destruction of non-mineralised connective 
tissue and bone.
In the recent years, more and more importance 
is attributed to the inflammatory process in the de-
velopment of chronic complications of diabetes. It is 
connected with the activation of defence mechanisms 
— referred to as the acute phase response [11, 12].
Both diabetes and diseases (mainly inflammatory) of 
the periodontal tissues are chronic disorders of multifac-
torial aetiology, which play an increasingly important 
role in the ageing of society and significantly lower the 
quality of patients’ life [8, 11].
The aim of the study was to assess the periodontal 
status and periodontal treatment needs in patients with 
non-controlled diabetes type 1 and type 2 (HbA1c > 7%), 
and to compare the results with the data obtained in a 
group of generally healthy people.
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The proportion of these patients was similar in sub-
group I — 3.8% and subgroup II — 3.4%. In the con-
trol group, theses patients accounted for 17.1%. The 
maximum value of CPITN = 1 was found in 11.7% of 
patients with non-controlled diabetes (total) and in 
23.8% of cases in the control group.
Subgroup I contained 19.2% of such patients and 
subgroup II far fewer at only 5.1%. People with CPITN 
Table I. The age and gender in the study group and the control group
Tabela I. Wiek i płeć w badanej grupie i grupie kontrolnej
Patient groups Age Gender
M % F %
Subgroup I 20–35 years old 9 26.4 12 33.3
36–51 years old 14 41.2 10 27.8
52–67 years old 11 32.4 14 38.9
Total: – 34 100 36 100
Subgroup II 20–35 years old 2 4.3 4 10.2
36–51 years old 20 43.5 17 43.6
52–67 years old 24 52.2 18 46.2
Total: – 46 100 39 100
Control group 20–35 years old 12 20.0 15 25.0
36–51 years old 22 36.7 23 38.3
52–67 years old 26 43.3 22 36.7
Total – 60 100 60 100
Table II. The number and percentage of toothless individuals in the study group and the control group
Tabela II. Liczba i odsetek osób bezzębnych w grupie badanej i w grupie kontrolnej
Toothlessness Subgroup I Subgroup II Control group Study group (total)
M F Total M F Total M F Total M F Total
Incidence n 10 8 18 16 10 26 9 6 15 26 18 44
% 29.4 22.2 25.7 34.8 25.6 30.6 15.0 10.0 12.5 32.5 24.0 28.4
None n 24 28 52 30 29 59 51 54 105 54 57 111
% 70.6 77.8 74.3 65.2 74.4 69.4 85.0 90.0 87.5 67.5 76.0 71.6
Total n 34 36 70 46 39 85 60 60 120 80 75 155
% 100 100 100 100 100 100 100 100 100 100 100 100
Statistical analysis: p < 0.0015
Table III. The average level of glycated haemoglobin HbA1c in the study group (depending on gender)
Tabela III. Przeciętne stężenie hemoglobiny glikowanej HBA1c w grupie badanej (w zależności od płci)
HBA1c Subgroup I Subgroup II Study group (total)
M F Total M F Total M F Total
Number 34 36 70 46 39 85 80 75 155
Standard deviation 1.15 1.58 1.38 1.86 1.3 1.63 1.49 1.44 1.52
Median 9.7 9.8 9.8 9.7 9.6 9.6 9.7 9.6 9.6
Mean value 9.43 9.51 9.47 9.68 9.36 9.53 9.57 9.43 9.5
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= 2 accounted for 16.2% of the study group and 21.9% 
of the control group. Subgroup I contained 25% of such 
patients and subgroup II 8.5%. The maximum value of 
CPITN = 3 was found in 36% of patients in the study 
group (total) and in 23.8% of the control group. Sub-
group I contained 28.8% of such patients and subgroup 
II much more at 42.4%. CPITN index = 4 occurred in as 
many as 32.4% of patients in the study group (in total) 
and in 13.3% of patients in the control group. Subgroup 
I accounted for 23.1% and subgroup II — 40.7%. The 
highest detected value of the index among all evalu-
ated groups of teeth determined the choice of a specific 
category of treatment needs (Table V). It may be noted 
that only 3.6% of patients in the study group (total) 
did not require treatment (TN0), including subgroup 
I — 3.8% and subgroup II — 3.4%. In the control group 
the percentage of these subjects was 17.1% and the dif-
ference showed statistical significance (p < 0.0010) in 
relation to the study group. The category of TN1 treat-
ment needs was found in the study group in 11.7%, 
while in the control group in 23.8% (p < 0.0196). This 
category of needs occurred three times more often in 
Table IV. The number and percentage of patients with maximum values of CPITN index in the study group and the control group
Tabela IV. Liczba i odsetek osób z maksymalnymi wartościami wskaźnika CPITN w grupie badanej i w grupie kontrolnej
Max. CPITN Subgroup I Subgroup II Control group Study group (total)
M F Total M F Total M F Total M F Total
0 n 1 1 2 0.0 2 2 4 14 18 1 3 4
% 4.2 3.6 3.8 0.0 6.9 3.4 7.8 25.9 17.1 1.9 5.3 3.6
1 n 5 5 10 0.0 3 3 13 12 25 5 8 13
% 20.8 17.9 19.2 0.0 10.3 5.1 25.5 22.2 23.8 9.3 14.0 11.7
2 n 5 8 13 1 4 5 16 7 23 6 12 18
% 20.8 28.6 25.0 3.3 13.8 8.5 31.4 13.0 21.9 11.1 21.1 16.2
3 n 8 7 15 13 12 25 10 15 25 21 19 40
% 33.3 25.0 28.8 43.3 41.4 42.4 19.6 27.8 23.8 38.9 33.3 36.0
4 n 5 7 12 16 8 24 8 6 14 21 15 36
% 20.8 25.0 23.1 53.3 27.6 40.7 15.7 11.1 13.3 38.9 26.3 32.4
Total: n 24 28 52 30 29 59 51 54 105 54 57 111
% 100 100 100 100 100 100 100 100 100 100 100 100
Table V. The needs for periodontal treatment in the study group and the control group
Tabela V. Potrzeby lecznicze przyzębia w grupie badanej i w grupie kontrolnej
Code of 
needs
Subgroup I Subgroup II Control group Study group (total)
M F Total M F Total M F Total M F Total
TN0 n 1 1 2 0.0 2 2 4 14 18 1 3 4
% 4.2 3.6 3.8 0.0 6.9 3.4 7.8 25.9 17.1 1.9 5,3 3.6
TN1 n 5 5 10 0.0 3 3 13 12 25 5 8 13
% 20.8 17.9 19.2 0.0 10.3 5.1 25.5 22.2 23.8 9.3 14.0 11.7
TN2 n 13 15 28 14 16 30 26 22 48 27 31 58
% 54.2 53.6 53.8 46.7 55.2 50.8 51.0 40.7 45.7 50.0 54.4 52.3
TN3 n 5 7 12 16 8 24 8 6 14 21 15 36
% 20.8 25.0 23.1 53.3 27.6 40.7 15.7 11.1 13.3 38.9 26.3 32.4
Total: n 24 28 52 30 29 59 51 54 105 54 57 111
% 100 100 100 100 100 100 100 100 100 100 100 100
TN0 0.0010
Statistical analysis: TN1 0.0196
TN3 0.0009
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subgroup I than II and amounted to 19.2% and 5.1%, 
respectively. The second category of treatment needs 
(TN2) concerned the greatest number of people, both 
in the study group (total) — 52.3% and in the control 
group — 45.7%. The removal of dental deposits was 
required by a similar proportion of patients in both 
subgroups. The comprehensive treatment of the peri-
odontium (TN3) was needed by as many as 32.4% of 
patients in the study group, and in 13.3% (p < 0.0009) 
of the generally healthy subjects. The number of such 
patients was almost twice as high in subgroup II — 
40.7% than in subgroup I — 23.1%.
Discussion
Many cross-sectional, long-term studies and illustrative 
works describe the adverse effects of diabetes on the 
development and severity of periodontal diseases [16]. 
These studies were carried out, however, in terms of 
narrowly formulated problems. The selection of indica-
tors to assess the periodontal status also had a diverse 
nature. According to Soskolne et al. [17], the dynamics 
of periodontal pathologies in diabetes depends on 
many factors, primarily on the degree of diabetic control 
and the presence of vascular complications. Long-term 
measure of diabetes control is via the determination of 
the glycated haemoglobin concentration. Numerous 
studies indicate a significant correlation between the 
parameters of diabetic metabolic control and the de-
velopment of chronic microvascular and macrovascular 
complications [9, 18, 19]. The severity of periodontal 
diseases in diabetes may be caused by an increase of 
collagenase activity, which leads to the prevalence 
of gingival destruction, immune disorders, and local 
and general intensive development of oral bacterial 
flora, particularly Gram-negative bacteria of the genus: 
Bacteroides, Fusobacterium, and Capnocytophaga. 
These bacteria may secondarily reduce the function 
of neutrophils by producing leucotoxins and thereby 
cause inflammation [1, 2, 19]. These factors probably 
all contribute to a more advanced and rapidly extend-
ing periodontal disease in people with non-controlled 
diabetes compared to healthy subjects [20, 21]. In 
addition, microangiopathy of the gingival blood vessels 
impairs the distribution of oxygen, the removal of waste 
products, and the leukocyte migration. Thus, it can be 
assumed that these factors impair the possibilities to 
repair and regenerate periodontal tissues in patients 
with diabetes.
Many publications describe the presence of the path-
ological periodontal pockets in patients with diabetes 
mellitus and the frequent loss of epithelial attachment 
compared to the healthy population [10]. According to 
Iacopino [22], this causes a reduction in the periodon-
tal adaptability, creating conditions for more frequent 
infections, both specific and non-specific. The above 
changes are favoured by local metabolic disorders and 
abnormal impaired macrophage chemotaxis of  neu-
trophils. A significantly greater increase in periodontal 
diseases was observed in patients with diabetes type 1 
compared with type 2 [17, 18] although Saito et al. [23] 
demonstrated a greater risk factor for these diseases 
in diabetes type 2. The assessment of the periodontal 
therapeutic needs of patients with diabetes suggests 
that the range is much greater than in generally healthy 
people, as shown by the values of CPITN index. This is 
confirmed by other authors. Rodrigues et al. [24] believe 
that the scope and nature of the needs in the treatment 
of periodontitis significantly distinguished patients 
with diabetes compared with generally healthy people, 
especially in terms of the removal of dental deposits. 
Other authors have shown instead a relatively frequent 
need for the surgical treatment of periodontal disease 
in diabetic patients [25, 26]. They stress the need to 
maintain constant metabolic control and absolute oral 
hygiene. Many researchers point out the great need 
for comprehensive treatment of periodontal disease in 
diabetics, including surgery — category TN3 [26–28]. 
The results of most authors are therefore consistent 
with the results of our studies and confirm the previous 
suggestions about the close relationship between non-
controlled diabetes and inflammatory processes of the 
periodontal tissues.
Conclusions
1. Patients with uncontrolled diabetes had significantly 
higher maximum value of CPITN = 3 and CPITN 
= 4. This was confirmed by the more advanced 
periodontal changes in this group, often requiring 
complex periodontal procedures together with 
surgery (category TN3).
2. Decompensated diabetes may be an important cause 
of changes in periodontal tissues and may cause 
a significant loss in masticatory function.
3. There is a need for close cooperation between 
diabetologists and dentists in order to use the most 
appropriate means and methods of treatment and 
significantly improve the quality of patient’s life.
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